The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase.
Epstein, L.F., Chen, H., Emkey, R., Whittington, D.A.(2012) J Biol Chem 287: 37447-37457
- PubMed: 22932897 
- DOI: 10.1074/jbc.M112.391425
- Primary Citation of Related Structures:  
4FNW, 4FNX, 4FNY, 4FNZ - PubMed Abstract: 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that, when genetically altered by mutation, amplification, chromosomal translocation or inversion, has been shown to play an oncogenic role in certain cancers. Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer ...